Compare AstraZeneca plc (AZN) vs Freshworks Inc (FRSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Freshworks Inc — how do they compare? AstraZeneca plc trades at $168.56 (market cap $253.13B), while Freshworks Inc trades at $10.67 (market cap $2.89B). The key difference: AstraZeneca plc is far larger — about 87.6× Freshworks Inc's market cap, and AstraZeneca plc pays a 1.92% dividend while Freshworks Inc pays none. Which is the better fit depends on your goals.
| AZN | FRSH | |
|---|---|---|
Market Cap | $253.13B | $2.89B |
Sector | Health | Technology |
52-Week High | $209.48 | $14.77 |
52-Week Low | $137.44 | $6.88 |
Enterprise Value | $279.37B | $2.15B |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Freshworks (FRSH) trades at $10.83, up 4.54% today, with a bullish technical signal from moving averages. The company shows strong fundamental improvement, with revenue growing from $498M in 2022 to $839M in 2025 and achieving profitability with a net income margin of 20.69%. Recent news highlights AI product launches and a strategic pivot to employee experience, with Q2 2026 earnings due August 4, 2026.
The outlook is positive given consistent revenue growth, high gross margins, and analyst consensus pointing to a 26% upside. Risks include execution of the new strategic focus and competitive pressures in the SaaS sector. The stock presents a value opportunity with a P/E of 17.63, below software industry averages, supported by improving cash flow trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Freshworks Inc
Freshworks Inc provides software as a service platform that enables small and medium-sized businesses to support customers through e-mail, phone, website, and social networks. It offers solutions that serve the needs of users in the CX and ITSM categories, and have also expanded its offering with Sales and Marketing automation products. These product offerings enable organizations to acquire, engage, and better serve their customers and employees.
Read more on FRSH →
